(Información remitida por la empresa firmante)
LUND, Sweden, July 18, 2023 /PRNewswire/ --
"The first half of 2023 showed 58% growth compared to the same period last year. The second quarter is always the weakest of the year for us, as it is the period when the number of colds is the lowest. Still, the second quarter was an intense period. Discussions on launches in some of the world's largest cold markets intensified and our research program continued. In August, we expect the results from two important scientific studies," said Claus Egstrand, CEO of Enzymatica.
The full report is available on: www.enzymatica.com/investors/financial-reports
This information is information that Enzymatica is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below, at 08:30 a.m. CET on July 18, 2023.
For more information, please contact:
Claus Egstrand, Chief Executive Officer, Enzymatica ABPhone: +44 7780 22 8385 | Email: claus.egstrand@enzymatica.com
Stefan Olsson, Communication Manager, Enzymatica ABPhone: +46 708 55 11 85 | Email: stefan.olsson@enzymatica.com
Enzymatica AB is headquartered in Lund, Sweden, and is listed on Nasdaq First North Growth Market.For more information, please visit www.enzymatica.se. Enzymatica's Certified Adviser is Erik Penser Bank.
The following files are available for download:
View original content:https://www.prnewswire.co.uk/news-releases/enzymatica-interim-report-q22023-an-exciting-and-important-time-ahead-301879378.html